Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myelomonocytic Leukemia (M4)
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT00096148
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 168
- Registration Number
- NCT00096135
- Locations
- 🇺🇸
CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloblastic Leukemia With Maturation (M2)de Novo Myelodysplastic SyndromesUntreated Adult Acute Myeloid LeukemiaAdult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Pure Erythroid Leukemia (M6b)Childhood Myelodysplastic SyndromesAdult Acute Eosinophilic LeukemiaAdult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 95
- Registration Number
- NCT00096122
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 61
- Registration Number
- NCT00093483
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT00093600
- Locations
- 🇺🇸
Dana Faber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
- Conditions
- Interventions
- Biological: Bleomycin SulfateBiological: FilgrastimDrug: CyclophosphamideDrug: CytarabineDrug: CisplatinDrug: Doxorubicin Hydrochloride (DOX)Drug: FluorouracilDrug: Leucovorin calciumDrug: EtoposideDrug: PentamidineDrug: PrednisoneDrug: IfosfamideDrug: Trimethoprim-SulfamethoxazoleDrug: MethotrexateDrug: Vincristine SulfateDrug: MethylprednisoloneDrug: Zidovudine (AZT)Radiation: Radiation Therapy
- First Posted Date
- 2004-10-05
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00002524
- Locations
- 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
- Conditions
- First Posted Date
- 2004-09-16
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Loyola University
- Registration Number
- NCT00004905
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 59
- Registration Number
- NCT00003671
- Locations
- 🇺🇸
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
🇺🇸West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸Madigan Army Medical Center, Tacoma, Washington, United States
Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
- First Posted Date
- 2004-09-06
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 20
- Registration Number
- NCT00003217
- Locations
- 🇺🇸
Children's Memorial Hospital, Chicago, Chicago, Illinois, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- Biological: filgrastimDrug: cladribineDrug: cytarabineDrug: etoposideDrug: methotrexateDrug: mitoxantrone hydrochlorideDrug: therapeutic hydrocortisoneProcedure: allogeneic bone marrow transplantationProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantationRadiation: low-LET cobalt-60 gamma ray therapyRadiation: low-LET electron therapyRadiation: low-LET photon therapy
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 115
- Registration Number
- NCT00002805
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.